Back to my company list

With Momentum

Exscientia

The AI engine Fit Assessment

Beta

Exscientia utilizes artificial intelligence and big data to enhance the process of drug discovery and development, focusing on designing and optimizing new drug candidates. Their platform has successfully delivered AI-designed drugs that have entered clinical trials, significantly improving productivity in the pharmaceutical industry.

Blurb

Exscientia is a pharmatech company that uses an end-to-end AI platform to design and discover new drugs.

HQ Location

Oxford (United Kingdom)

Founded

2012

Employees

201 - 500

Total funding raised

$3.67B

Last Funding Event

Acquired by Recursion Pharmaceuticals, August 2024

Smart insights

  • Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
  • Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
  • 6m headcount growth: 25%
  • 1Y headcount growth: 94%
  • Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
  • Drug Discovery Optimization

Exscientia combines human expertise with AI and machine learning to enhance drug discovery. The company focuses on precision engineering of medicine candidates, enabling faster and more efficient development of new treatments. By integrating innovative experimental techniques, Exscientia aims to improve patient outcomes and revolutionize the pharmaceutical industry.